





,F+ cSisl;.1"l ci,nJ lirl ..r*t"'*'JK etL *E ;l*lt
:
:,ilJ:.
ccL-z,ccr-) ,:i ! fSr" cEl^ sQl olx-o +r ccR-5 .,ilS.r.S or,j$ ,l+r .rr;ll
-,ojL s.^-.,YE +, $.- .rlrt+tt t. (4,CCL-5
Gyy l:aj c* d : L. ..S
,rl[,}, ;F,-,a ;*,,,--)Li tS.r : L^:^l_r ll':."t





Kerman University of Medical Science, Department of Hematology and Blood Banking,
Molecular Medicine Research center
Title:
" 
Expression of chemokine CCR-5 receptor along with its ligand (CCL-2, CCL-4, CCL-5) in




















j .) ule)U2l:. ;0,
. v /.
>.: \ \.:agrf arl,
,.'-rllb q L-r,J
! "'+Iy l;j? +
,-:." L L-y;.;o1:












t elt ,:*.# F ,.i -i .ty*ly;l ,-r-l; J1* .,<Jj dta ,st!- )l ,6.,:4* JL";il ,srl*)9jL .,-Vb :.i,u 9 ao.loo
a4319".r{.,l.b;1511 
.}--ljij l.i ar..p-l.pl t )++"a 9,;r;) JL";*J9| ;l -r,-.r-;.<*Jr. *.i1 .''. ltLrltt* aS .11 79;y9f
g*Yb- 9 P 6r c& orl5.+,"*.,J"1, O*",,|+a,r*-l .56 ci)l-:.iaL.srl:;9 tg.ty c;U -1.. +"bl .512 6 .ny" ,e
,rrlf ,, cj.4d Lts ,i-.:) ,-.- 9:\!l .c-l o$:Q:;-,_r+5.116 4t4. I G* ,rtl*,.r*fi.sl^ .,,-LrL:11 r+ t+i t la
,r.Sr.5 9 l.a ,,-5p_L azx;a 6Lx Jl- d*l lr .ll+Jl L_lr;1: l1 *-+r oJ ,r*-l 6-*- L.l, 4,-l 1.: al :1lr )rjL u-Vb l-:i
,sl^f$9.i1aJl Lr".i dl.u,j.gr"S 9 l-o.1,-6p-Lu;st-d;,-lfl alt-!.tlrt* o-lIrs^r,.,l4rl eJE.i-15.r. l9l l-t
9.;nl oY)L>I pti'J-l )).l;*a.li:eu*s; t\*dli\)l ,s*"1,:$,,:.,Li-l-ooJ;,59lo;r.6r.5.r;b:99.r,\rJl
: 
,rr, t, c*,fJ 
-)+qd jl *-l;.:) c*-; J-,r ,,-l;,b.s-,l:;Li-lo ,sr5 9 g.lS93;:;Y)4:il )l tl ,;y.,r+ JE _,).;Qll
.rrlr 
.g1L- c",--rl .5;9J;t r: rl91 lyl
p-;lrr; (CCL-Z, CCL-4, CCL-5)"--bsKJ , CCR-5 .ti*t a.S# ,-,1;n ,-r"ty. a, ,v-rl: -r-!i aJlt" e,-l -,r L
alrgCBC d/.,).rr. dr-.,L*;l c,-L-rr.J!1.!li &tl"i U" b;lba";9;l.ril ,.srlL; 
-:r9. allt .i-1::Qj9;9 rl7
.rt^.r-lJrJ c-E-G ;,::-r,-; 
":.s.5 ,lS u"-)";i ty ,e.E J; l*Sli t , ,spy.!"*.iJ3 t CC-5 O!.ri o,=-5 .L-; t-9;)'tf
..r,-.:ri j;l obVtl 
.51ei6e i.p 4 jl o:kil L &il;le.: glp),{!l l*f )f ,t\i rrt l;-Yl .<;* q CCL-2. CCL-4,CCL-5
.s el+l SPSS ,t;t p;22 *;-;1i c:G:- L lao:i.: J*b. e *;;
p-0i001) ,r 
.rY! uli o9f o c*; .511.:.;,. t* q ry otf ry r.: b sl(.j d$# e*-,FL dJu. 6,-l; .r,Ll2 :tAdiit-
At* .srl,-L+ "5;5, ;l ":lc.l ! .p.,t -;l .r9*; ,lr .+- !9 cib ;,-l;il .uLi ogrS a,. i .-; );9" otF r: CCf-5 jj !L .(ValUe <
.o;l: 
.5rb .r* .J--lll .roLi "9f t .*- ,l;r* .r1^ r*-# !-- ,, CCr-5
'r-iu s, J,tli..5la;15,11 J r*N G)* ) 6l ":;:3 'qt t'. Olaa 1': ';)l'- o'r* '$;" c'('- or-:o: uf ,s)l *-vb :dr54'dj
:ff ! .:r, cr cr,rL* o,,rr JP 1r .;-11 6.*- :-1y ;r gul: 
"p-lpl 
ect )9jL s-Vb .!l J* 1,: *;--l n;.*- .sla .r"r-) 1l o,:tril
! "/t olrll ;rlr gLl .,tL:" a;1.,;4!: oUit- b.t e F q. Ls)r|-,*-V1j ijiq r).r-- o*.*-.d=-.gG a,J9. .al ;.r-i
.)r fhrl *-Yl; c"-7-"r. r: **-l ,|-l9c
,.,-U,f,; Ji-Yl, 6 ;- 9+- +,CCR-5,ir-ltr.Jli,)rrL GdYb :lAoj tg f/5
Expression of chemokine CCR-5 receptor along with its ligand (CCL-2, CCL-A, CCL-S)
in patients with thalassemia major
Introduction & Objective:
Thalassemia major is an autosomal recessive disorder, a common genetic disease caused by
mutation in the B globin gene located on chromosome 1 1. That patients with a severe
hemolytic anemia are exposed from the first year of life, as well as with age, with defective
body organs. They need blood transfusion to survive. Safety anomalies The fourth predictor
of the cause of B-thalassemia deaths is suggested after cardiac failure, infectious
complications, and liver disease. Inflammation and immune deficiency play an important role
in the side effects of B-thalassemia major, in which the immune system plays an important
role in inflammatory conditions with various types of cytokine and chemokine secretion cells.
"A chronic inflammation state in these patients with elevated levels of cytokines and
'proinflammatory chemokines and inflammatory markers. Chemokines and their receptors are
involved in a wide range of highly pathologic pathologies. Essentially all of the immune and
inflammatory disorders in your venhicle have some of the discomforts in the chemokine and
thgir receptors. Therefore, the biology of the migration of leukocytes and the understanding of
this process in the pathology is very important.
In this study, we intend to study the CCR-5 receptor chemokine and its ligands (CCL-2, CCL-
4,CCL-')
Materials and Methods:
In a case-control study, the specimens were firstly matched in terms of age and, with
satisfaction of the patient, a blood sample was taken in the CBC tube and the clot was taken
by the personnel. CC-5 expression was tested by flow cytometry technique and with Real time
technique. The concentration of CCL-2, CCL-4, CCL-5 and CCL-5 chemokines was
evaluated by ELISA technique. Demographic information was obtained using a data
collection form. Data analysis was performed using SPSS version 22.
Results:
Based on the results of this study, the chemokine levels of ligands in the serum of the case
group were significantly higher than the control group (p-value <0.001). The expression of
CCR-5 in the case group was increased, but not significant. On the other hand, by using flow
cytometry, expression of CCR-5 on the level of leukocytes in patients was significantly higher
than that of the control group.
Conclusion:
Thalassemia major represents a major health problem in the world with a wide range of
complications from various organs. The use of immune systems in the clinical practice of
thalassemia major increases the knowledge about the immune system during the course of the
disease. With the emergence of the importance of various immune components in the
pathogenesis of thalassemia, it seems necessary to carry out more detailed studies to illustrate
the potential effects of safety factors on thalassemia management.
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